The Clinical Practice of Palliative Sedation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-20

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Palliative Sedation (PS) is defined as the intentional lowering of consciousness of a patient in the last phase of life, to relieve patients suffering from refractory symptoms. For those symptoms all possible effective treatments, within an acceptable timeframe, are exhausted.

Several studies have been performed about palliative sedation, mostly focusing on continuous deep sedation, with the use of various measurements to monitor its effect. Efficacy of continuous palliative sedation has been monitored by agitation/distress levels, symptom control, levels of sedation/awareness, comfort, safety and family/caregivers satisfaction. Differences between studies occur, for instance in definition, application and monitoring. Consequently reported outcomes and associated treatment goals differ between studies which makes it difficult to compare the results.

Within this international multicenter observational study, the investigators aim to evaluate the effects of palliative sedation on patient's comfort levels. Participants with different forms and intensity of palliative sedation (intermittent and continuous, from light to deep) are included in a prospective design as part of an international study.

Objectives:

1. To evaluate the effect of palliative sedation on participants' comfort and other symptoms in different international hospices, palliative care units and hospital ward settings.
2. To assess the clinical practice of palliative sedation in different international care settings and the accompanying costs and consequences.

Study design: Prospective observational multicentre study in hospices, palliative care units and hospital ward settings in five European countries (Belgium, Germany, Italy, Spain, The Netherlands).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit

NCT02198404

Refractory Pains End of Life Patients

COMPLETED PHASE4

Efficiency and Safety of a Procedural Sedation by Propofol on Terminally Ill Patients With Refractory Pain

NCT02734511

Refractory Pains

COMPLETED PHASE3

Influence of Sevoflurane and Propofol on Maximum Muscular Strength, Speed of Contraction and Relaxation

NCT05615025

Anesthesia, General Neuromuscular Transmission Disorders

COMPLETED PHASE3

Endotracheal Intubation Without Muscle Relaxants

NCT03112564

Muscle Relaxation Intubation Complication

COMPLETED NA

Sevoflurane PharmacokInetics in ARDS

NCT04023305

Acute Respiratory Distress Syndrome

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Palliative Sedation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults;
* with advanced cancer;
* and a limited life expectancy (1- 2 months);
* according the health care team, intractable distress caused by one or more refractory symptoms can be expected or is present during the hospitalization.

Participants can enter Phase 2 of this study when fulfilling the following preconditions:

* participant is suffering from intractable distress caused by one or more refractory symptoms according the health care team and/or participant and relatives;
* sedative medication is started with the aim to relieve burden of otherwise intractable suffering (palliative sedation)

Exclusion Criteria

* a potential participant is unable to give informed consent;
* a potential participant is unable to speak and read in the native language of the participating country.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No